A systematic review of four injection therapies for lateral epicondylitis: prolotherapy, polidocanol, whole blood and platelet-rich plasma

Author
Rabago, D., Best, T., Zgierska, A., Zeisig, E., Ryan, M., Crane, D.

Published
2009

Journal Title
British Journal of Sports Medicine

DOI
https://doi.org/10.1136/bjsm.2008.052761

Copyright Statement
Copyright remains with the authors 2009. The attached file is reproduced here in accordance with the copyright policy of the publisher. For information about this journal please refer to the journal’s website or contact the authors.
A systematic review of four injection therapies for lateral epicondylitis: prolotherapy, polidocanol, whole blood and platelet-rich plasma

D Rabago, T M Best, A E Zgierska, E Zeisig, M Ryan and D Crane


Updated information and services can be found at:
http://bjsm.bmj.com/cgi/content/full/43/7/471

These include:

References
This article cites 61 articles, 17 of which can be accessed free at:
http://bjsm.bmj.com/cgi/content/full/43/7/471#BIBL

Rapid responses
You can respond to this article at:
http://bjsm.bmj.com/cgi/eletter-submit/43/7/471

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Editor's choice (432 articles)
Complementary medicine (805 articles)

Notes

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to British Journal of Sports Medicine go to:
http://journals.bmj.com/subscriptions/
A systematic review of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol, whole blood and platelet-rich plasma

D Rabago,1 T M Best,2 A E Zgierska,3 E Zeisig,4 M Ryan,5 D Crane6

ABSTRACT

Objective: To appraise existing evidence for prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injection therapies for lateral epicondylitis (LE).

Design: Systematic review.

Data sources: Medline, Embase, CINAHL, Cochrane Central Register of Controlled Trials, Allied and Complementary Medicine. Search strategy: names and descriptors of the therapies and LE.

Study Selection: All human studies assessing the four therapies for LE.

Main results: Results of five prospective case series and four controlled trials (three prolotherapy, two polidocanol, three autologous whole blood and one platelet-rich plasma) suggest each of the four therapies is effective for LE. In follow-up periods ranging from 9 to 108 weeks, studies reported sustained, statistically significant (p<0.05) improvement in visual analogue scale primary outcome pain score measures and disease-specific questionnaires; relative effect sizes ranged from 51% to 94%; Cohen’s d ranged from 0.68 to 6.68. Secondary outcomes also improved, including biomechanical elbow function assessment (polidocanol and prolotherapy), presence of abnormalities and increased vascularity on ultrasound (autologous whole blood and polidocanol). Subjects reported satisfaction with therapies on single-item assessments. All studies were limited by small sample size.

Conclusions: There is strong pilot-level evidence supporting the use of prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injections in the treatment of LE. Rigorous studies of sufficient sample size, assessing these injection therapies using validated clinical, radiological and biomechanical measures, and tissue injury/healing-responsive biomarkers, are needed to determine long-term effectiveness and safety, and whether these techniques can play a definitive role in the management of LE and other tendinopathies.

The precise cause of degeneration and pain in patients with a tendinopathy is not clear; mechanical, vascular, neural and “failure of healing” aetiological models have all been proposed.13 Treatment approaches for LE vary widely and lack definitive evidence. Non-steroidal anti-inflammatory drugs and corticosteroid injections have traditionally been used but have not been shown to be more effective than watchful waiting in the long term.14 Polidocanol, prolotherapy, autologous whole blood and platelet-rich plasma (PRP) injection therapies have reported promising outcomes for LE and other sport-related tendinopathies. Polidocanol is a vascular sclerosant. In treating tendinopathy, it is used to sclerose areas of high intratendinous blood flow, sometimes termed “neovessels”, which are seen histopathologically12 and in vivo under high resolution ultrasound with colour Doppler. Neovascularity is thought to be associated with the underlying mechanism of LE and other overuse tendinopathies,20 though whether it is a causal agent in the pathophysiology of tendinopathy is not clear.22 A recent study reported that sustained sclerosis of neovascularity in LE was a good predictor of positive clinical effect at 2 years.25 Several randomised controlled trials (RCTs) and prospective case series have reported positive effects of polidocanol therapy for patellar, epicondylar and Achilles tendinopathies.26

The use of prolotherapy dates to the 1930s, when it was developed for pain associated with presumed ligament laxity. Although several injection agents have been used, hyperosmolar dextrose and morrhuate sodium (also a vascular sclerosant) are the most popular and best studied agents. A recent systematic review identified 42 studies, over 50% of which evaluated prolotherapy for back pain, the remainder largely for painful conditions such as osteoarthritis and injuries associated with ligament laxity.29 Prolotherapy has also been used to treat tendinopathy of elite athletes and LE.31

Lateral epicondylosis (LE) (“tennis elbow”) is an important condition of the upper extremity with an incidence of up to 4–7/1000 patients per year, having a substantial impact on athletes and workers. A subset of patients are refractory to non-surgical therapy including relative rest, eccentric exercise and corticosteroid injections and suffer long-term pain and disability on average lasting for 6 months to 2 years, regardless of therapy.5 7 Our understanding of the pathophysiology of lateral elbow overuse injury has changed in recent years.5 11 The pathophysiological hallmark of tendinopathy is the presence of degenerative changes, including neovascularity and disorganised collagen fibres.9 12
Platelet-rich plasma is prepared from autologous whole blood, which is centrifuged to concentrate platelets in plasma. The intention is to augment the native healing process at the site of pain through the action of platelet-derived growth factors (PDGFs). Platelets contain at least six PDGFs vital to bone and soft tissue healing. The use of PRP is being intensely studied and reports suggest that clinical use is increasing rapidly for LE,38 rotator cuff repair,37 38 acute and chronic muscle strain, muscle fibrosis, ligamentous sprains, and joint capsular laxity (David Crane, MD, personal communication).

These therapies, which target the diseased tendon tissue directly, may interrupt the degenerative cycle associated with tendinopathy and allow the return of the native healing process, ultimately leading to improvement in clinical outcomes. None have been directly compared in any trial setting, but each has been assessed for LE. Because of the potential for prolotherapy, polidocanol, whole blood and PRP injection therapies to be effective for tendinopathies, we undertook a systematic review of the literature for each technique for the treatment of refractory LE.

METHODS
Inclusion criteria included human clinical trials of any design involving pre- and post-treatment assessment evaluating any of the four injection therapies for LE. A literature search was performed by the lead author (DR) and library staff of the following electronic databases: Medline (Ovid Web, 1950–2008 and Medline In-process & Other Non-Indexed Citations), Embase (1974–2008), CINAHL (1982–2008), the Cochrane Central Register of Controlled Trials (through third quarter 2008) and Allied and Complementary Medicine (1985–2008). Search strategies utilised the name of each intervention and the names of the injectants (table 2). Reports not cited in the databases above were searched using the Google search engine and the National Institutes of Health (NIH) CRISP electronic database using relevant anatomical descriptors and therapy names. The reference lists of identified studies were reviewed to identify potentially eligible studies. E-mail or phone contact was attempted with relevant author(s) or principal investigator(s) of included articles or abstracts when additional information was needed.

Identification of eligible studies
The titles and abstracts of all identified studies were screened by the study librarian and the lead author (DR). Studies whose title and abstract clearly indicated that the paper met criteria were reviewed. A description of excluded studies follows.

Data extraction
The data collection strategy for the methods and results sections of identified papers was determined a priori. Data from prospective case series was extracted by the lead author (DR). Two unblinded authors (DR, TB) assessed each controlled study. Data were extracted using a pre-existing technique.39 The RCT strength was assessed using the Delphi40 controlled trial internal validity assessment. Disagreements were resolved by consensus. Using these instruments, the methods and results of each study were described and an overall quality score assigned. Where possible, several measures of “effect size” at various follow-up time points were calculated by the authors. (1) “Per cent improvement” was calculated for all intervention arms as the change in pain score divided by the baseline score multiplied by 100%. (2) Cohen’s d was used as published or, if not provided, was calculated according to one of two formulas: (a) for controlled trials, $d = (M_1 - M_2)/SD_{pooled}$ where $M_1$, $M_2$ were the means in the two groups, and $SD_{pooled} = \sqrt{\left[ SD_1^2 + SD_2^2 \right]/2}$; (b) for pre–post assessments, $d = |mean of the pre–post difference|/SD of the mean; if data for formula “b” was not available, then formula “a” was applied, when possible. 5) In one study,33 effect size was estimated based on the Z value of the Wilcoxon Signed Rank Test according to the formula: $Z/N$, where N equals the number of observations over the two time points.41 An overall evidence grade for each technique was assigned by the lead author (DR) based on the Strength of Recommendation Taxonomy criteria.42

RESULTS
The search identified 21 reports as possibly relevant; the abstract of each was reviewed. Nine studies met the eligibility criteria. Excluded studies were: general reviews (three), surgical (one), basic science (one), for different indications (three) or editorials (two), or assessed a non-reviewed therapy (one).

<table>
<thead>
<tr>
<th>Growth factor</th>
<th>Source</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transforming growth factor-beta, TGF-β</td>
<td>Platelets, extracellular matrix of bone, cartilage matrix, activated T cells and natural killer cells, macrophages/monocytes and neutrophils</td>
<td>Stimulates undifferentiated mesenchymal cell proliferation; regulates endothelial, fibroblastic and osteoblastic mitogenesis; regulates collagen synthesis and collagenase secretion; regulates mitogenic effects of other growth factors; stimulates endothelial chemotaxis and angiogenesis; inhibits macrophage and lymphocyte proliferation</td>
</tr>
<tr>
<td>Basic fibroblast growth factor, bFGF</td>
<td>Platelets, macrophages, mesenchymal cells, chondrocytes, osteoblasts</td>
<td>Promotes growth and differentiation of chondrocytes and osteoblasts; mitogenic for mesenchymal cells, chondrocytes and osteoblasts</td>
</tr>
<tr>
<td>Platelet-derived growth factor, PDGFa-b</td>
<td>Platelets, osteoblasts, endothelial cells, macrophages, monocytes, smooth muscle cells</td>
<td>Mitogenic for mesenchymal cells and osteoblasts; stimulates chemotaxis and mitogenesis in fibroblasts/glia/ smooth muscle cells; regulates collagenase secretion and collagen synthesis; stimulates macrophage and neutrophil chemotaxis</td>
</tr>
<tr>
<td>Epidermal growth factor, EGF</td>
<td>Platelets, macrophages, monocytes</td>
<td>Stimulates endothelial chemotaxis/ angiogenesis; regulates collagenase secretion; stimulates epithelial/ mesenchymal mitogenesis</td>
</tr>
<tr>
<td>Vascular endothelial growth factor, VEGF</td>
<td>Platelets, endothelial cells</td>
<td>Increases angiogenesis and vessel permeability; stimulates mitogenesis for endothelial cells</td>
</tr>
<tr>
<td>Connective tissue growth factor, CTGF</td>
<td>Platelets through endoosteosis from extracellular environment in bone marrow</td>
<td>Promotes angiogenesis, cartilage regeneration, fibrosis and platelet adhesion</td>
</tr>
</tbody>
</table>

Table 1 Synopsis of growth factors contained in platelet-rich plasma

<table>
<thead>
<tr>
<th>Growth factor</th>
<th>Source</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transforming growth factor-beta, TGF-β</td>
<td>Platelets, extracellular matrix of bone, cartilage matrix, activated T cells and natural killer cells, macrophages/monocytes and neutrophils</td>
<td>Stimulates undifferentiated mesenchymal cell proliferation; regulates endothelial, fibroblastic and osteoblastic mitogenesis; regulates collagen synthesis and collagenase secretion; regulates mitogenic effects of other growth factors; stimulates endothelial chemotaxis and angiogenesis; inhibits macrophage and lymphocyte proliferation</td>
</tr>
<tr>
<td>Basic fibroblast growth factor, bFGF</td>
<td>Platelets, macrophages, mesenchymal cells, chondrocytes, osteoblasts</td>
<td>Promotes growth and differentiation of chondrocytes and osteoblasts; mitogenic for mesenchymal cells, chondrocytes and osteoblasts</td>
</tr>
<tr>
<td>Platelet-derived growth factor, PDGFa-b</td>
<td>Platelets, osteoblasts, endothelial cells, macrophages, monocytes, smooth muscle cells</td>
<td>Mitogenic for mesenchymal cells and osteoblasts; stimulates chemotaxis and mitogenesis in fibroblasts/glia/ smooth muscle cells; regulates collagenase secretion and collagen synthesis; stimulates macrophage and neutrophil chemotaxis</td>
</tr>
<tr>
<td>Epidermal growth factor, EGF</td>
<td>Platelets, macrophages, monocytes</td>
<td>Stimulates endothelial chemotaxis/ angiogenesis; regulates collagenase secretion; stimulates epithelial/ mesenchymal mitogenesis</td>
</tr>
<tr>
<td>Vascular endothelial growth factor, VEGF</td>
<td>Platelets, endothelial cells</td>
<td>Increases angiogenesis and vessel permeability; stimulates mitogenesis for endothelial cells</td>
</tr>
<tr>
<td>Connective tissue growth factor, CTGF</td>
<td>Platelets through endoosteosis from extracellular environment in bone marrow</td>
<td>Promotes angiogenesis, cartilage regeneration, fibrosis and platelet adhesion</td>
</tr>
</tbody>
</table>
Differences in the methods of the four therapies and in outcome measures used prevented pooling of data. Heterogeneity and inter-rater agreement of controlled study quality scoring were not formally assessed. First authors were queried about ambiguous elements of their studies. There was no significant disagreement between the raters.

Study outcomes

We identified nine eligible reports, four controlled studies and five prospective case series evaluating effects of prolotherapy (three), polidocanol (two), autologous whole blood (three) and PRP (one) therapies for LE assessing 208 adult subjects (tables 3,4). The common primary inclusion criteria were elbow pain for a minimum of 2 months and being refractory to one or more conservative therapies. The subjects were 19–66 years old, diagnosed with LE due to a variety of work and recreational activities. No study reported the inclusion of elite athletes. Subjects had an average pain duration ranging from 2 to 102 months. Subjects in three studies25 35 45 underwent ultrasound evaluation as part of the diagnosis and injection protocol and had areas of structural change and neovascularisation within the common extensor tendon. The controlled studies25 31 36 44 were of moderate to high quality, scoring 5–9/9 on the Delphi assessment. All controlled studies compared active solution with a comparison solution with either vasoactive control agents (lidocaine/adrenaline or bupivacaine/adrenaline)25 36 or saline.31 The primary outcome of each study was pain on a visual analogue scale (VAS) or pain questionnaire,44 though the denominator and specific issue addressed varied slightly. Improvement ranged from 51%25 to 94%46 for the active groups compared with baseline status; Cohen’s d effect size ranged from 0.6825 to 6.68,31 indicating a strong effect. Cohen’s d was not calculated for some studies due to insufficient data.25 36 45 46

In a prospective case series47 of subjects receiving ultrasound-guided polidocanol treatment, VAS scores improved by 37% at 3 months (p<0.05) and by 55% at 8 months (p<0.01). Grip strength significantly improved at 3 and 8 months. Structural defects and vascularity on ultrasound were improved at 8 months. In a subsequent double-blind RCT, Zeisig et al25 compared polidocanol with vasoconstrictive lidocaine/adrenaline injections. Both groups improved their VAS pain scores at 3 months, without significant differences between the groups. Three months following the first treatment session, subjects in both study groups who were unsatisfied with clinical results were offered an additional injection session with polidocanol. Follow-up at 12 months after enrolment showed that additional polidocanol injections improved VAS scores by 51% and 47% compared with baseline in subjects receiving initial polidocanol and adrenaline injection respectively.

In two RCTs,31 44 and one prospective case series,46 subjects received either prolotherapy or normal saline. Active subjects in Scarpone et al reported improvement of 90% at 16 weeks compared with 22% for controls (p<0.001), with four prolotherapy subjects reporting complete pain resolution. In a small RCT, Glick et al, subjects reported 66% improvement on a disease-specific questionnaire compared with 11.5% for controls (p = 0.09). In a prospective case series, Lyftogt45 reported 94% improvement compared with baseline scores using a novel subcutaneous injection technique (p<0.05).

Three prospective case series assessing autologous whole blood were identified.35 46 47 Each study reported significant (p<0.05) improvement compared with baseline: Edwards et al reported 88%;47 Gani et al reported 64%46 and Connell et al35 reported a median score of 0.

In a non-randomised controlled trial36 comparing a single treatment session of PRP with control injections, PRP subjects improved by a mean of 81% by 27 weeks. PRP subjects were further followed to a mean of 25.6 months, at which point the authors reported 95% pain reduction compared with baseline. Controls reported 17% improvement at 4 weeks; three of five control subjects dropped out before the 8 week follow-up and the remaining two control subjects were not followed further.

Secondary outcome measures also improved in all eight studies. Mishra et al29 reported significant improvement on the Mayo Elbow-Performance Index. Each study assessing whole blood injections reported significant improvement in Nirschl scores.35 46 47 Zeisig et al25 and Scarpone et al29 reported significant improvement in maximal grip strength compared with baseline in the intervention groups. Scarpone et al also reported improved isometric strength in the prolotherapy group compared with controls. Zeisig et al25 and Connell et al29 reported decreased structural defects and neovascularity on ultrasound, though these were not reliably correlated with clinical gains. Treatment satisfaction on single-item assessments was reported by 78% of the “polidocanol only” subjects at 12 months,25 by 93% of the PRP subjects at 25.6 months,46 and by 100% of subjects in Lyftogt et al.45 Scarpone et al46 reported that prolotherapy subjects qualitatively reported maintenance of treatment effects at 12 months.

DISCUSSION

Prolotherapy, polidocanol, autologous whole blood and PRP injection therapies have received attention in the treatment of tendinopathies among elite athletes and primary care patients. This is the first systematic review to compare these techniques for a single condition, LE. Each of the studies reviewed is small, and their methodological limitations prevent a consensus recommendation on the use of any of the three therapies compared with another at this time. However, the large effect sizes reported by all studies are compelling and suggest several areas of clinical, theoretical and research interest.

Clinical implications

In a technique that places injectant on or near a degenerative area of the tendon–bone insertion, each injectant appears safe. Though not powered to detect rare local or systemic negative effects, no study evaluating any of these therapies for musculoskeletal conditions has reported serious adverse events. Two systematic reviews of prolotherapy29 48 and a study of negative consequences of prolotherapy25 reported only minor side effects consistent with injection trauma, suggesting that the prolotherapy injectants themselves are safe. Though vascular sclerosants can theoretically cause tissue necrosis, this was not reported in these studies. The transmission of blood-borne disease is a possibility in each therapy, and underscores the need for universal precautions, including the use of gloves and appropriate handling and disposal of medical waste.

With moderate-to-large effect sizes that far exceed minimal clinically relevant effect sizes for chronic pain,49 which are sustained over 1220 33 to 25 months46 compared with baseline or comparison groups, each technique appears potentially effective for refractory LE, thus expanding treatment options for patients who have failed conservative care. In one author’s clinic (EZ) the stepwise treatment algorithm for LE is: (1) conservative measures including eccentric exercise, (2) polidocanol injections,
Table 3  Clinical trials of prolotherapy (PrT), polidocanol (Pdl), autologous whole blood (AWB) and platelet-rich plasma (PRP) injection therapies for LE

<table>
<thead>
<tr>
<th>Study/Type</th>
<th>Subjects</th>
<th>Intervention</th>
<th>Injectant/control</th>
<th>Ancillary treatment</th>
<th>Follow-up/outcome measures</th>
<th>Results</th>
<th>Effect size of pain score (Cohen’s d and % improvement)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zeisig et al 2008&lt;sup&gt;c&lt;/sup&gt;</td>
<td>36</td>
<td>Polidocanol RCT</td>
<td>Pdl: at 0 weeks, and optional at 12 weeks; U/S-guided, to “neovessels”; after their 1st injection session (in Pdl or comparison group), all subjects were offered Pdl injections at 12 weeks if unsatisfied with effects of first injection: 0.5–1 ml total</td>
<td>None</td>
<td>12, 52 weeks;</td>
<td>▶ no between-group differences in pain score, grip strength or satisfaction;</td>
<td>Compared with baseline: At 12 weeks, unsatisfied control subjects were crossed-over to Pdl injections, if desired</td>
<td></td>
</tr>
</tbody>
</table>
| Polidocanol RCT               | 25       | Pdl: at 0 weeks, and optional at 12 weeks; U/S-guided, to “neovessels”; after their 1st injection session (in Pdl or comparison group), all subjects were offered Pdl injections at 12 weeks if unsatisfied with effects of first injection: 0.5–1 ml total | Pdl: 10 mg/ml; active comparison group: lidocaine + adrenaline; optional Pdl injections at 12 weeks (cross-over) | Pain improved by 28 points at 12 weeks and 41 points at 35 weeks (p<0.05); grip strength, presence of structural defect and degree of vascularity improved at 12 and 35 weeks (p<0.05); | 9 | Cohen’s d: N/A  
  Pdl improved: 2%, adrenaline improved: 1%  
  Pdl improved: 51% (p<0.05), adrenaline/Pdl improved: 4%  
  52 weeks:  
  Cohen’s d: N/A; Pdl improved: 51% (p<0.05), adrenaline/Pdl improved: 4%  
  35 weeks:  
  grip strength, presence of structural defect and degree of vascularity improved at 12 and 35 weeks (p<0.05); |
| Zeisig et al 2006<sup>c</sup>  | 11       | Polidocanol prospective case series | Pdl: at 0 weeks; 0.4–1.1 ml total | None | 12, 35 weeks; | | Compared with baseline: Prospective case series N/A |
| Polidocanol prospective case series | 1 (7 female); mean age 46 (33–63) years; LE pain for mean 23 months; failed >1 of: PT (7), NSAIDs (11), steroid injection (7), orthotics (5), acupuncture (2), ultrasound (2) | 0.4–1.1 ml total | | | Pain improved by 29 points at 12 weeks and 41 points at 35 weeks (p<0.05); grip strength, presence of structural defect and degree of vascularity improved at 12 and 35 weeks (p<0.05); | 35 weeks: |  

Continued
<table>
<thead>
<tr>
<th>Study/Type</th>
<th>Subjects</th>
<th>Intervention</th>
<th>Injectant/control</th>
<th>Ancillary treatment</th>
<th>Follow-up/outcome measures</th>
<th>Results</th>
</tr>
</thead>
</table>
| Scarpone et al 2008 PROLO | 24 (13 female); mean age 45.7 (19–62) years; LE pain for mean 1.9 years; failed NSAIDs, relative rest, PT, two steroid injections | PrT: at 0, 4, 8 weeks, to tender points at supraspinatus ridge, lateral epicondyle and annular ligament; 1.5 ml total | PrT: 10.7% dextrose + 14.7% sodium morrhuate | None                     | 8, 16, 52 weeks                                                                 | Mean subject satisfaction 83%  
At 16 weeks, pain improved (p<0.05) by 4.6 points compared with baseline, and 3.6 points compared with control;  
Compared with baseline: Lack of consistent, long-term follow-up; unconventional assessment of grip strength |
| Glick et al 2008 PROLO    | 8 (2 female), mean age 50 years; LE pain for longer than 3 months | PrT: at 0, 3 and 6 weeks to the lateral epicondyle and tender extensor tendon origin; 5 ml total | PrT: 15% dextrose and 1% lidocaine | All subjects used at-home stretching | 9 weeks; McGill Pain Questionnaire (0–45), Physical Composite score of MOS SF-36 | McGill score improved (p = 0.086) by 7.75 points compared with baseline and 7 points compared with control;  
Physical Composite score improved (p<0.05) by 8.4 points compared with baseline and control. Cohen’s d statistic calculated to be 1.57 and 1.78 for the McGill and MOS measures respectively  
Compared with baseline: Lack of disease-specific outcome measure, short follow-up period |
| Lyftogt 2007 PROLO        | 20 (9 female), mean age 39 (24–64) years; LE pain for mean 6 months | PrT: weekly sessions for mean 8 weeks; to tender points at common extensor tendon; 0.5–1.0 ml total | PrT: 20% glucose + 0.1% lidocaine | Modified daily activity | Weekly during intervention (mean duration of 7.2 weeks); final follow-up at mean 19 months; | Pain improved by 6.8 points compared with baseline (p<0.05);  
Compared with baseline: Unconventional subcutaneous prolotherapy technique with 10–15 injections per session |
<table>
<thead>
<tr>
<th>Study/Type</th>
<th>Subjects</th>
<th>Intervention</th>
<th>Injectant/control</th>
<th>Ancillary treatment</th>
<th>Follow-up/outcome measures</th>
<th>Results</th>
<th>Effect size of pain score (Cohen’s d and % improvement)</th>
<th>Comments</th>
<th>Delphi score, x/9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edwards et al 2003</td>
<td>28 (14 female); LE pain for at least 3 months; failed two or more conservative therapies</td>
<td>Autologous Whole Blood</td>
<td>Prospective case series</td>
<td>AWB: at 0, 6 weeks, and optional at 12 weeks; extensor carpi radialis brevis; 2 ml total</td>
<td>Placebo: N/A</td>
<td>elbow pain (0–10 VAS); subject satisfaction (yes/no)</td>
<td>100% of subjects satisfied</td>
<td>mean 19 months: Cohen’s d: N/A Improved: 94% (p &lt; 0.05) Compared with baseline: Prospective case series; no statistical comparisons reported</td>
<td>N/A</td>
</tr>
<tr>
<td>Cornell et al 2006</td>
<td>35 (12 female); mean age 40.9 (26–62) years; LE pain for mean 13.8 months; failed each of: rest, PT, steroid injection</td>
<td>Autologous Whole Blood</td>
<td>Prospective case series</td>
<td>AWB: 0, 4 weeks, and optional at 8 weeks; U/S-guided, to area of maximal structural discontinuity; 2 ml total</td>
<td>Control: N/A</td>
<td>pain at rest (0–10 VAS); Nirschl scale (1–7)</td>
<td>Nirschl scale improved by 4.5 points by a mean of 3 weeks after last injection</td>
<td>after first injection: Cohen’s d: 1.7 Improved: 40% (p &lt; 0.05); after second injection: Cohen’s d: 3.0 Improved: 88% (p &lt; 0.05)</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Continued
### Table 3 Continued

<table>
<thead>
<tr>
<th>Study/Type</th>
<th>Subjects</th>
<th>Intervention</th>
<th>Injectant/control</th>
<th>Ancillary treatment</th>
<th>Follow-up/outcome measures</th>
<th>Results</th>
<th>Effect size of pain score (Cohen’s d and % improvement)</th>
<th>Comments</th>
<th>Delphi score, x/9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gani et al. 2007**</td>
<td>26 (16 female); mean age 34 (21–54) years; LE pain for mean 2.1 years;</td>
<td>AWB: at 0 weeks, and optional at 6 weeks</td>
<td>AWB: whole autologous blood</td>
<td>Sling for 1 week, then rest and stretching exercises; no heavy lifting for 3 weeks</td>
<td>Weekly, up until 35 weeks on average;</td>
<td>Pain improved (p &lt; 0.05) by 2.1 points at 35 weeks;</td>
<td>Compared with baseline: Prospective case series;</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Autologous Whole Blood</td>
<td>failed rest, NSAIDs; activity modification, steroid injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prospective case series</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mishra et al. 2006***</td>
<td>20 adults; 15 PRP subjects: mean age 48.1 years, LE pain for mean 15.3 months; five control subjects: mean age 42 years, LE pain for mean 11.8 months; failed one or more of: NSAIDs, PT, bracing, steroid injection</td>
<td>PRP: single injection at 0 weeks</td>
<td>PRP: pH 8.4, approximately 3.3 million platelets per treatment session</td>
<td>Stretching exercises for 2 weeks, then formal strengthening exercise programme for 2 weeks</td>
<td>8, 26, 108 weeks;</td>
<td>At 8 weeks, pain improved (p &lt; 0.05) by 33 points compared with control; compared with baseline, pain improved (p &lt; 0.05) by 47, 71 and 80 points at 8, 26 and 108 weeks, respectively;</td>
<td>Compared with baseline: Non-randomised design; three of five control subjects left study at 8 weeks; injected local anaesthesia used in both groups; 108 - week Mayo score not reported</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Platelet-Rich Plasma non-randomised controlled trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AWB, autologous whole blood; LE, lateral epicondylitis; N/A, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs; PdT, polidocanol; PRP, platelet-rich plasma; PrT, prolotherapy; PT, physical therapy; U/S, ultrasound; VAS, visual analogue scale.

*Median scores reported, per cent change therefore not calculated; Cohen’s d calculated using reported Z statistic.

Results reported for a final follow-up unless stated otherwise.
### Table 4: Comparison of the Strength of Evidence Taxonomy (SORT) recommendation and methodological considerations for each injection therapy when used to treat lateral epicondylosis, as practised in assessed papers

<table>
<thead>
<tr>
<th>Injectant</th>
<th>SORT recommendation</th>
<th>Anatomical evaluation</th>
<th>Injectant preparation</th>
<th>Added injectants</th>
<th>Injection technique</th>
<th>Volume injected</th>
<th>Injection schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polidocanol</td>
<td>2B</td>
<td>Palpatory exam, U/S and Colour Doppler exam; elbow structures are examined while seated, with arm resting on a table in 70–80 degrees of elbow flexion and wrist pronation</td>
<td>None; stock polidocanol 10 mg/ml solution used</td>
<td>None</td>
<td>U/S and Colour Doppler-guided injections at the common extensor origin at the lateral epicondyly. The aim is to inject polidocanol intravascularly; however, due to the small size of neovessels, the solution may be delivered perivascularly.</td>
<td>0.4–1.1 ml; one injection, using three to five needle sticks to ensure coverage of neovessels</td>
<td>One to two injection sessions, approximately 3 months apart</td>
</tr>
<tr>
<td>Autologous Whole Blood</td>
<td>3C</td>
<td>Palpatory exam ± U/S exam</td>
<td>2 ml autologous whole blood collected at the time of injection</td>
<td>Topical anaesthetic</td>
<td>Injection to undersurface of extensor carpi radialis brevis or area of maximal tendon disruption on U/S exam</td>
<td>2 ml</td>
<td>Study-dependent; one to three injection sessions, approximately 1 month apart</td>
</tr>
<tr>
<td>Platelet-Rich Plasma</td>
<td>2B</td>
<td>Palpatory exam</td>
<td>Preparation of syringes with anticoagulant, then 20–60 ml of whole blood is drawn from peripheral vein</td>
<td>Proprietary, kit-dependent; anticoagulant</td>
<td>U/S-guided single injection, using five to seven needle sticks, 1 cm distal to the origin of the common extensor tendon</td>
<td>1 ml per cm² of involved tissue, up to total of 2–3 ml</td>
<td>Single injection session</td>
</tr>
<tr>
<td>Prolotherapy</td>
<td>1B</td>
<td>Palpatory exam</td>
<td>None; injectant prepared from stock solution of 50% dextrose and 5% mornhuate sodium</td>
<td>Saline and topical anaesthetics: lidocaine and sensorcaine</td>
<td>Injection at tender entheses of ligament and tendon structures at the lateral epicondyly and supracondylar ridge; precise location and number of injections per session as well as the number of sessions per treatment course are patient-specific, determined by exam</td>
<td>0.5 ml per injection, three to five injections per session</td>
<td>3 monthly sessions</td>
</tr>
</tbody>
</table>

U/S, ultrasound
and (5) surgery, which, in the author’s experience, is rarely required. A similar algorithm has been reported for Achilles tendinopathy.20

The ease of clinical application of these techniques varies. Each requires routine medical knowledge of diagnostic, anatomical and joint injection skills. However, the procurement and processing of the injectants, and the required assessment associated with each therapy, vary. For example, polidocanol therapy calls for ultrasound and colour Doppler exam and specialised skills to visualise increased vascularity. PRP therapy requires investment in a centrifuge and blood processing equipment, and corresponding skills. Individual characteristics of the platelet preparation differ slightly between companies based on a number of factors; several reviews are available.35 37 Prolotherapy has limited start-up costs and is the easiest to implement. However, it may be more labour-intensive; in the reviewed studies, it required three treatment sessions, whereas the other three therapies typically used one or two treatment sessions.

Theoretical implications

The cause of pain in LE and the precise mechanism of action of the four injectants are unclear. The reviewed studies offer an opportunity to address aspects of both issues. Researchers have suggested that clinical effects of these therapies may in part result from the compressive effects of injected solutions, needle trauma, and irritant effects of blood.25 29 The studies, however, suggest that the “active” group injectants themselves provide the majority of therapeutic effects. No significant volume-related effect of comparison saline or dilute adrenaline injection was found in three RCTs.31 36 44 Similarity in outcomes in Zeisig et al’s35 study may be explained by the actions of the two solutions: vasosclerosis may have a slightly greater effect on the neurovascular milieu than does temporary vasoconstriction. However, the study design did not allow additional adrenaline injections, so whether polidocanol is more effective than adrenaline for LE remains unclear. Mishra et al found no significant effect from mild preinjection fenestration. It is unclear whether the more active fenestration performed by Connell et al influenced outcomes, as no other study reported such a preinjection procedure.

The notion that these injectants exert a biological effect independent of needle trauma or volume-related effects is consistent with clinical, animal model and in vitro evidence. Recent clinical studies documented that areas of increased vascularity are associated with painful LE,38 have significant sensory innervation, and are linked with higher concentrations of the pain modulators glutamate and calcitonin gene-related peptide.39 Sclerosing of such structures in Achilles and patellar tendinopathy has also led to reduction in pain.24 26

Prolotherapy with dextrose with or without morrhuate sodium has been reported to decrease pain and improve function in a variety of tendinopathies.38 39 44 The historical hypothesis that prolotherapy causes an inflammatory response leading to reduced tendon and ligament laxity40 has not been confirmed. Two recent studies did not detect increased inflammation or decreased laxity following prolotherapy in a rat model.38 39 Morrhuate sodium is in the same chemical class as polidocanol and likely acts as a vascular sclerosant. Animal model data support a biological effect. Rabbit medial collateral ligaments injected with morrhuate sodium were significantly stronger (51%), larger (47%), thicker (28%) and had larger collagen fibre diameter (56%) than saline-injected controls.29 Rat patellar tendons injected with morrhuate sodium were able to withstand a mean maximal load of 136% of the uninjected control tendons.40 Hyperosmolar dextrose is also a mild vascular sclerosant, though its potential effect in tendinopathy is not well understood. A hyperosmolar glucose environment has been shown to increase platelet-derived growth factor expression and upregulate multiple mitogenic factors40 45 that may act as signalling mechanisms in tendon repair. Lyftogt has suggested that neurogenic inflammation40 may contribute to pain in LE, and that subcutaneous injections of hyperosmolar dextrose target inflamed branches of the posterior antebrachial and medial antebrachial cutaneous nerves (Lyftogt personal communication, 2008). However, neither growth factor nor “neurosclerotic” effects have been confirmed in a tendinopathy model.

PRP injections make use of activated platelets which discharge bioactive signalling molecules including three adhesion molecules and seven growth factors. A total of 21 of 28 clinical reports, largely from the maxillo-facial and wound care fields, have reported positive PRP effects on bone and wound healing. However, many studies had a small sample size and used different methods for platelet processing, thereby preventing definitive conclusions.39 Most PRP-related in vitro and animal model science reports come from the orthopaedic literature on bone healing and report a variety of cellular and growth factor effects of potential importance to tendon healing.40 Studies assessing PRP effects for soft tissue healing showed increased anabolic gene expression in horse flexor tendons40 and proliferation of tendon cells and production of VEGF.40 46 Two large animal studies have recently reported improved healing of repaired dog and porcine cruciate ligaments following PRP therapy.67 68

Research implications

Basic science research is needed to elucidate the mechanism of action for each injection therapy. Sufficiently powered clinical trials should evaluate efficacy and effectiveness of each of the therapies compared with eccentric exercise and with each other. Research would benefit from the unification of outcome measures across these studies, which should include clinically relevant, patient-reported and objectively assessed outcomes such as pain, function and disability. Assessment of tissue injury/healing-sensitive biomarkers may enhance our understanding of the processes underlying treatment efficacy.

What is already known on this topic

Therapies for lateral epicondylosis and other overuse tendinopathies are varied; none have been found to definitively reduce pain and improve function. Data suggestive of efficacy for prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injections have been reported in limited, pilot-level studies but have not been directly compared.

What this study adds

This systematic review compares studies assessing prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injections for a single tendinopathy, lateral epicondylosis. Nine studies document a large effect size for each technique; “per cent change compared with baseline” and “Cohen’s d” ranged from 51% to 94%, and 0.68 to 6.68, respectively.
Existing preliminary data suggest that these injection therapies have a disease-modifying potential; therefore, imaging studies, such as MRI and/or ultrasound with colour Doppler, may also be useful in addressing the mechanisms by which these agents promote healing. Whether results can be generalised across different patient populations (e.g. athletes and occupational workers) remains an important question to be answered. Larger studies assessing PRP, prolotherapy and autologous stem cell injection for LE are currently in progress (personal communication: Allan Mishra, Ron Glick and David Connell).

CONCLUSIONS

Existing data for prolotherapy, polidocanol, autologous whole blood and PRP injection therapies for refractory LE suggest effectiveness, but are limited by lack of large definitive trials. These therapies appear safe and effective when performed by an experienced clinician. Positive results have been reported in case series and non-randomised and randomised studies with LE from a variety of sport and work-related causes. Future studies using validated clinical measures, and radiological, biomechanical and tissue injury/healing-responsive biomarkers, as secondary outcome measures are needed to determine whether these injection techniques can play a definitive role in a cure for LE and other tendinopathies.

Acknowledgements: Leslie Christensen, MA-US, AHP, Medical Librarian, St. Mary’s Hospital Medical Center, for assistance with design and implementation of the search strategy for this study.

Competing interests: DC Massachusetts is a consultant and lecturer for Harvest Hospital Medical Center, for assistance with design and implementation of the search

REFERENCES


63. Zochodne DW. Local events within the injured and regenerating peripheral nerve trunk: The role of the microenvironment and microcirculation. Biomedical Review 1997;8:37–54.


